Advanced or metastatic non-small cell lung cancer (NSCLC) is characterised by a poor
prognosis and few second-or third-line treatments. First-generation epidermal growth factor …

Non‐small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor
prognosis once the disease has progressed past the point at which surgery is a viable …

The discovery that a number of aberrant tumorigenic processes and signal transduction
pathways are mediated by druggable protein kinases has led to a revolutionary change in …

Precision oncology is now the evidence-based standard of care for the management of
many advanced non-small cell lung cancers (NSCLCs). Expert consensus has defined …

Personalized therapy has significantly developed in lung cancer treatment over recent
years. VEGF and EGF play a major role in non-small-cell lung cancer (NSCLC) tumor …

Tumor tissue biomarkers are the basis for targeted therapy in non-small cell lung cancer
(NSCLC). These biomarkers either reflect the target of the specific drug or some factor that …

The incidence and mortality of lung cancer rank top three of all cancers worldwide.
Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) …

Non-small cell lung cancer (NSCLC) is one of the most lethal malignancies accountings for
nearly 80% of all lung cancer cases diagnosed and causing over one million deaths …

Introduction: Lung cancer (LC) is the most common neoplasm worldwide, and 85% of these
tumors are classified as non-small cell lung cancer (NSCLC). LC treatment was initially …

Historically, patients with advanced stage non‐small cell lung cancer (NSCLC) were treated
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …